Loading…
Practice changing cervical cancer clinical trials
•Cemiplimab treatment is efficacious in patients with recurrent or metastatic cervical cancer (cvx ca).•Pembrolizumab with chemotherapy is active and FDA approved in first line treatment of recurrent/metastatic PDL-1 + cvx ca.•Tisotumab Vedotin (TV) received FDA accelerated approval for treatment of...
Saved in:
Published in: | Gynecologic oncology 2022-06, Vol.165 (3), p.410-412 |
---|---|
Main Authors: | , , , , , , , , , |
Format: | Article |
Language: | English |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | •Cemiplimab treatment is efficacious in patients with recurrent or metastatic cervical cancer (cvx ca).•Pembrolizumab with chemotherapy is active and FDA approved in first line treatment of recurrent/metastatic PDL-1 + cvx ca.•Tisotumab Vedotin (TV) received FDA accelerated approval for treatment of recurrent/metastatic cvx ca after chemotherapy.•Transformative advances in cvx ca result from collaborations with GOG-P, ENGOT, other global partners and industry sponsors.•Sequencing includes:1) pembrolizumab with first line chemotherapy 2) TV in second line or pembrolizumab if checkpoint naïve. |
---|---|
ISSN: | 0090-8258 1095-6859 |
DOI: | 10.1016/j.ygyno.2022.03.004 |